Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal : a cohort study, 2018–2021

Loading...
Thumbnail Image

Authors

Johnston, Candice Leigh
Ngassa Piotie, Patrick
Maposa, Innocent
Singh, Sandhya
Kuonza, Lazarus R.
De Voux, Alex

Journal Title

Journal ISSN

Volume Title

Publisher

AOSIS

Abstract

BACKGROUND: The Central Chronic Medicines Dispensing and Distribution (CCMDD) programme facilitates clinically stable patients to collect their chronic medication from community-based pick-up points. AIM: We determined baseline glycaemic control and rates and predictors of becoming suboptimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients. SETTING: The setting of the study was eThekwini, KwaZulu-Natal, South Africa. METHODS: We performed a cohort study (April 2018- December 2021). We linked T2DM CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with ≥ 1 repeat-test available. We used Kaplan–Meier analysis to assess survival rates and extended Cox regression to determine associations between time to sub-optimal control (HbA1c > 7%) and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are reported. RESULTS: Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per national guidelines was associated with a lower hazard of sub-optimal glycaemic control (aHR: 0.46; 95% CI: 0.24–0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher hazard of sub-optimal glycaemic control (aHR: 1.50; 95% CI: 1.16–1.95; p-value = 0.002) versus monotherapy. CONCLUSIONS: The HbA1c monitoring, in-line with testing frequency guidelines, is needed to alert the CCMDD programme of patients who become ineligible for enrolment. Patients receiving dual-therapy require special consideration. CONTRIBUTION: Addressing identified shortfalls can assist programme implementation.

Description

DATA AVAILABITY STATEMENT: Permissions to publish were granted by the NDoH, the NHLS and the CCMDD Programme. The data that support the findings of this study are available from third parties, namely, the CCMDD and NHLS. Restrictions apply to the availability of these data, which were used under licence for this study. Data are available from the authors with the permission of the CCMDD and NHLS.

Keywords

CCMDD programme, Glucose control, Survival analysis, eThekwini, Glycaemic control, Central chronic medicines dispensing and distribution (CCMDD), Type 2 diabetes mellitus (T2DM), SDG-03: Good health and well-being, SDG-09: Industry, innovation and infrastructure

Sustainable Development Goals

SDG-03:Good heatlh and well-being
SDG-09: Industry, innovation and infrastructure

Citation

Johnston, L.C., Ngassa Piotie, P., Maposa, I., et al. Determinants of sub-optimal glycemic control among patients enrolledin a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018–2021. African Journal of Primary Health Care and Family Medicine 2024;16(1), a4336.https://doi.org/10.4102/phcfm.v16i1.4336.